Unique Pharm

Unique Pharmaceutical Laboratories is a major pharmaceutical division of J.B. Chemicals & Pharmaceuticals Ltd, headquartered in Mumbai, India. The company is recognized as a global leader in the production of medicated lozenges and maintains a strong presence in the branded generics market across emerging and developed economies. Its core therapeutic focus areas include gastroenterology, cardiology, nephrology, and anti-infectives, with flagship brands such as Metrogyl, Rantac, and Cilacar. Unique Pharm operates multiple state-of-the-art manufacturing facilities that hold approvals from stringent regulatory authorities including the US FDA, UK MHRA, and EU GMP. In addition to its own product portfolio, the company provides extensive contract manufacturing and development services (CDMO) to international pharmaceutical firms. Since 2020, the parent company has been majority-owned by the global investment firm KKR, which has accelerated its expansion into chronic therapy segments.